减瘤性肾切除术30天并发症与死亡率的当代分析
基于ACS-NSQIP数据库2011至2016年行根治性肾切除术的15869例患者,其中1322例(8%)为转移性癌症。转移性癌症患者轻微和严重并发症、再手术率、非计划再入院率及术后30天死亡率均显著更高。应重视减瘤性肾切除术的手术风险分层与患者咨询。
要点
- 转移性癌症患者行减瘤性肾切除术的围手术期并发症显著多于非转移性根治性肾切除术患者。
- 转移性癌症患者再手术率、非计划再入院率及术后30天死亡率均显著更高。
- 选择减瘤性肾切除术候选者时应进行仔细的手术风险分层和适当的患者咨询。
核心结论
- 行减瘤性肾切除术的患者围手术期结局显著差于无转移证据的行根治性肾切除术的患者。
研究设计与样本
- 回顾性分析ACS-NSQIP数据库2011至2016年间行根治性肾切除术的患者共15869例,其中1322例(8%)存在转移性癌症。
主要发现
- 转移性癌症患者轻微并发症(P< .01)和严重并发症(P< .01)更多。
- 转移性癌症患者再手术率更高(P< .01)。
- 转移性癌症患者非计划再入院率更高(P< .01)。
- 转移性癌症患者术后30天死亡率更高(P< .01)。
临床怎么用
- 选择减瘤性肾切除术候选者时应进行仔细的手术风险分层和适当的患者咨询。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To examine the rates of adverse surgical outcomes in patients undergoing cytoreductive nephrectomy (CN) compared to patients undergoing radical nephrectomy in the nonmetastatic setting using a large administrative database. METHODS: Patients in the American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP) who underwent a radical nephrectomy between 2011 and 2016 were included. Patients were stratified by the preoperative variable of presence or absence of metastatic cancer. Perioperative outcomes were compared. A multivariable logistic regression analysis was performed to test the association between patients with metastatic cancer and perioperative morbidity and 30-day mortality. RESULTS: There were 15,869 total patients included in this analysis of whom 1322 (8%) patients had metastatic cancer. Of the entire cohort, the majority of patients were over 60 years old (58%) and 9621 (61%) were male. Seventy-three of the patients were Caucasian. Patients with metastatic cancer had more minor (P< .01) and major (P< .01) complications, a higher rate of reoperation (P< .01), and a higher rate of unplanned readmissions (P< .01). Finally, the cohort with metastatic cancer had a higher rate of postoperative 30-day mortality (P< .01) than patients without metastatic cancer. CONCLUSION: Patients undergoing a CN have significantly worse perioperative outcomes than patients undergoing a radical nephrectomy without evidence of metastases. Careful surgical risk stratification and appropriate patient counseling should be undertaken when selecting candidates for CN.
引用
- May DN, Hill H, Matrana MR, et al. A Contemporary Analysis of the 30-day Morbidity and Mortality Associated With Cytoreductive Nephrectomy. Urology. 2020. PMID: 33203521. doi:10.1016/j.urology.2020.10.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。